IMA203CD8 in Positive Solid Cancers

• Showcasing the manufacturing strategy behind IMA203 to meet the dosing demands of PRAME-positive solid tumours
• Connecting manufacturing innovation with clinical impact by enabling high-dose TCR therapies for solid tumours and supporting the advancement of emerging clinical data in nextgeneration cell therapies

Speakers:

Ali Mohamed

Senior Vice President - CMC

Immatics